Filing Details
- Accession Number:
- 0001127602-21-004635
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-09 15:02:45
- Reporting Period:
- 2021-02-08
- Accepted Time:
- 2021-02-09 15:02:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 794172 | Meridian Bioscience Inc | VIVO | In Vitro & In Vivo Diagnostic Substances (2835) | 310888197 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1714030 | Jr. Mccune John Rice | 3471 River Hills Drive Cincinnati OH 45244 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-02-08 | 10,000 | $13.55 | 23,712 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-02-08 | 17,205 | $10.46 | 40,917 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-08 | 16,480 | $28.16 | 24,437 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2021-02-08 | 10,000 | $0.00 | 10,000 | $13.55 |
| Common Stock | Stock Options (Right to Buy) | Disposition | 2021-02-08 | 17,205 | $0.00 | 17,205 | $10.46 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2027-08-08 | No | 4 | M | Direct | |
| 0 | 2030-01-30 | No | 4 | M | Direct |
Footnotes
- Prices range from $27.47 per share to $28.62 per share. The reporting person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
- These options were awarded under the 2012 Stock Incentive Plan and vested 25% every 40 days from the August 8, 2017 grant date.
- These options were awarded under the 2012 Stock Incentive Plan and vested 25% every 90 days from the January 29, 2020 grant date.
Billionaire Hedge Funds
